Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.52 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.52 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18494109 | 0.87 | GAA (0.56) | ALDH1A1L3MBTL1PTPN1 | |
| SCHEMBL4834504 | 0.87 | ALDH1A1 (0.57) | ALDH1A1LMNATSHRRAB9AHSD17B10 | |
| SCHEMBL4529848 | 0.85 | HPGDS (0.59) | ALDH1A1LMNAPTPN1KDM4EHPGDS | |
| SCHEMBL11671935 | 0.85 | ALDH1A1 (0.59) | ALDH1A1LMNATSHRRAB9AHSD17B10 | |
| SCHEMBL503962 | 0.83 | ALDH1A1 (0.61) | ALDH1A1LMNATSHRRAB9AHSD17B10 | |
| SCHEMBL30393029 | 0.83 | ALDH1A1 (0.61) | ALDH1A1LMNATSHRRAB9AHSD17B10 | |
| SCHEMBL4539589 | 0.83 | ALDH1A1 (0.60) | ALDH1A1LMNATSHRRAB9AHSD17B10 | |
| SCHEMBL4524352 | 0.83 | MAPT (0.55) | ALDH1A1LMNARAB9AAVPR1AAVPR1B | |
| SCHEMBL13209664 | 0.82 | MRE11 (0.43) | ALDH1A1LMNATSHRRAB9AHSD17B10 | |
| SCHEMBL13447246 | 0.82 | ALDH1A1 (0.59) | ALDH1A1LMNATSHRRAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20050176791-A1 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1474140-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2004-11-10 | — | — | EP | disclosed |
| US-20040010022-A1 | 5-HT2B receptor antagonists | ASTERAND, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003068226-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | ALDH1A1 1363/4885LMNA 3744/4885TSHR 191/4885 |
| US-20050176791-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR3B | ALDH1A1 2700/4885LMNA 4134/4885TSHR 71/4885 |
| US-20040010022-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR2C | ALDH1A1 974/4885LMNA 3528/4885TSHR 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.